Rallybio (RLYB)
(Real Time Quote from BATS)
$1.19 USD
-0.05 (-4.03%)
Updated Aug 28, 2024 01:12 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RLYB 1.19 -0.05(-4.03%)
Will RLYB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RLYB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RLYB
Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock?
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
RLYB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Rallybio Corporation (RLYB) Could Rally 202.36%: Here's is How to Trade
Does Rallybio Corporation (RLYB) Have the Potential to Rally 290.63% as Wall Street Analysts Expect?
Down -19.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Rallybio Corporation (RLYB)
Other News for RLYB
Rallybio to Present at Upcoming Investor Conferences
Rallybio price target lowered by $3 at H.C. Wainwright
Rallybio GAAP EPS of -$0.67 misses by $0.30, revenue of $0.3M
RLYB Stock Earnings: Rallybio Misses EPS for Q2 2024
Buy Rating Justified by Rallybio’s Financial Stability and Promising Clinical Trials